Moreover, Brodalumab is proven effective in other IL-17-driven inflammatory diseases, i.e psoriasis, rheumatoid arthritis, and psoriatic arthritis, indicating its potential in Th17-high asthma (92, 93). Here, IL17A is linked to asthma.